Vernalis plc [VNLS] CEO to Ring the NASDAQ Stock Market Closing Bell

NEW YORK, May 17  /PRNewswire-FirstCall/ -- The following is being issued by NASDAQ (NASDAQ:NDAQ):

What:

Simon Sturge, CEO of Vernalis plc (NASDAQ:VNLS) will preside over the closing bell.

  Where:
  NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio

  When:
  Thursday May 18th, 2006 at 4:00 p.m. EDT

  Contacts:
  Gregory Gin
  Lazar Partners Ltd.
  212-867-1762
  

  NASDAQ MarketSite:
  Stephanie Lowenthal; 646.441.5220



Feed Information: The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17.  The downlink frequency is 4040 Vertical; Audio 6.2-6.8 The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at [phone].

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Vernalis plc [VNLS]:

Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists.  The Company has two marketed products, Frova(R) and Apokyn(R), and a development pipeline focused on neurology and central nervous system disorders.  The company has seven products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Serono.  Vernalis has established a U.S. commercial operation to promote Apokyn(R) and co-promote Frova(R) alongside its North American licensing partner, Endo Pharmaceuticals, propelling the Company towards its goal of becoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceutical company.  For further information about Vernalis, please visit http://www.vernalis.com/.

On May 8, 2006, Vernalis announced top-line data from the Company's second Frova(R) (frovatriptan succinate) Phase III efficacy study for Prevention of Menstrual Migraine.  The full press release, Frova(R) Meets Primary Endpoint in Second Phase III Study for Prevention of Menstrual Migraine; Data to be Included as Part of Supplemental NDA to FDA, can be accessed at http://www.vernalis.com/ver/nc/latestreleases/releases2006/2006-05-08/. 

DATASOURCE: NASDAQ



CONTACT:  Gregory Gin of Lazar Partners Ltd., [phone],

, for Vernalis; or Stephanie Lowenthal of NASDAQ

MarketSite, [phone]



Web site:  http://www.nasdaq.com/

http://www.vernalis.com/ 

Copyright